When AI purchases bypass normal IT requisition and review, organisations often miss privacy, security, and suitability checks. That increases the chance of using a tool outside its intended purpose, such as a research tool in clinical decision support. It also leaves boards and managers without a clear mitigation plan, which can expose patient data and create compliance risk.
Why unreviewed healthcare AI purchases create avoidable exposure
When healthcare teams buy AI tools outside normal security and procurement review, the main problem is not just weak process, it is blind spots in how the tool handles data, integrations, permissions, and downstream clinical use. A tool that looks useful in isolation may still be unsuitable for patient-facing, regulated, or decision-support settings once security, privacy, and operational context are examined.
That gap matters because healthcare AI is rarely a single-purpose application. It can touch patient records, reporting workflows, clinical documentation, messaging, and vendor infrastructure, so the buying decision should account for data flow, access boundaries, and who is accountable if the tool behaves unexpectedly.
Where the failure usually starts
The failure is often organisational rather than technical. A clinician, department, or pilot team may adopt a tool for speed, but without procurement and security involvement there is no structured check on vendor terms, data retention, integration scope, or whether the intended use matches the actual risk profile of the workflow.
That is how a research assistant can drift into clinical support, or a productivity tool can quietly become part of a patient-data workflow. The issue is not only misuse by staff, it is also role confusion: the organisation may assume the tool is low risk because the purchase was small, while the tool is actually processing sensitive data at scale.
This is why governance needs to cover both the business purchase path and the technical control path. Security review should look at data exposure, authentication, logging, and third-party dependencies, while procurement should ensure there is a vetted contract, named owner, and approved use case before rollout.
Why healthcare teams should treat AI buying as a control point
AI buying decisions create a practical control point for healthcare organisations because they determine whether a tool enters the environment with enough scrutiny to be safely used. A narrow focus on functionality can miss whether the product stores prompts, trains on submitted content, calls external services, or exposes information to users beyond the intended care team.
For that reason, the buying process should be treated as part of security architecture, not just vendor management. The right question is not only whether the tool works, but whether the organisation can justify its use, constrain its scope, and explain the safeguards if it becomes part of a regulated workflow.
That also includes ownership. If no one is accountable for security testing, data review, and approval of clinical use, the tool can remain in a grey zone for months. In practice, that is where shadow adoption becomes a governance problem, because staff may rely on a system that was never formally accepted into the control environment.
Risk and Threat Considerations
Unreviewed healthcare AI purchases increase exposure because they can bypass privacy checks, third-party risk review, and role-based approval before patient data is processed. The result is often a mismatch between the tool’s real behaviour and the organisation’s assumptions about how safely it is being used.
Failure mechanism: A tool is adopted without security and procurement review, so data handling, access, and intended use are not validated before staff start using it with sensitive information. That can leave undocumented data flows, unsupported clinical use, and unmanaged vendor dependence.
Impact: The organisation may expose patient data, use AI outside its intended purpose, and face compliance, audit, and accountability gaps if the tool influences care or processes regulated information.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and NIST CSF 2.0 set the technical controls, while ISO/IEC 27001:2022 and GDPR define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | SA-4 — Acquisition Process | Healthcare AI buying needs security requirements built into procurement. |
| RA-3 — Risk Assessment | AI tools should be assessed for data, workflow, and vendor risk before use. | |
| Recommendation — Embed security and privacy requirements in the acquisition review. Assess the tool’s operational and privacy risks before approval. | ||
| ISO/IEC 27001:2022 | A.5.19 — Information security in supplier relationships | Third-party AI tools introduce supplier and data-handling risk. |
| A.5.21 — Managing information security in the ICT supply chain | AI purchases can add supply-chain exposure through vendors and dependencies. | |
| Recommendation — Review supplier obligations before allowing healthcare data use. Verify supplier and dependency controls before deployment. | ||
| GDPR | Art.25 — Data protection by design and by default | Patient-data AI use needs privacy built in before deployment. |
| Recommendation — Apply privacy-by-design checks before any patient-data rollout. | ||
| NIST CSF 2.0 | GV.SC-01 — Supply Chain Risk Management Strategy | AI procurement is a supply-chain and vendor-risk decision. |
| Recommendation — Use a supply-chain risk strategy for AI vendor selection and approval. | ||
Practitioner Guidance
What to verify: Confirm who approved the tool, what data it can ingest, where that data is stored or transmitted, and whether the vendor contract matches the actual use case. If those answers are unclear, the tool is not ready for broad deployment.
Decision rule: If the AI tool can touch patient information, clinical workflows, or internal systems, require security and procurement sign-off before production use. If it is only a low-risk experiment, keep it isolated from real data and make that boundary explicit.
What good looks like: The organisation can name the business owner, security owner, approved purpose, and control set for each AI tool, and can show that the tool is not being used beyond the scope originally reviewed.
Practitioner takeaway: The real risk is not simply buying the wrong AI product, it is allowing an unreviewed product to become part of healthcare operations before anyone has verified its data handling, scope, and accountability.
Related resources from NHI Mgmt Group
- What happens when security teams try to buy AI SOC tools through a slow procurement process during an active incident?
- How should security teams handle risks from AI browser extensions?
- How should security teams govern API keys used for generative AI access?
- How should security teams control copy-paste into AI tools without blocking normal work?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 27, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
